Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia

被引：13
|
作者：
George, Binsah [1 ]
Kantarjian, Hagop [1 ]
Jabbour, Elias [1 ]
Jain, Nitin [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
IMMUNOTHERAPY | 2016年 / 8卷 / 02期
关键词：
acute lymphoblastic leukemia; antibody drug conjugate; inotuzumab; monoclonal antibody; ACUTE LYMPHOCYTIC-LEUKEMIA; ANTIBODY-TARGETED CHEMOTHERAPY; ACUTE MYELOID-LEUKEMIA; B-CELL LYMPHOMAS; HYPER-CVAD; GEMTUZUMAB OZOGAMICIN; CD22-TARGETED IMMUNOCONJUGATE; MONOCLONAL-ANTIBODY; ANTITUMOR EFFICACY; ADHESION MOLECULE;
D O I：
10.2217/imt.15.108
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients.
引用
收藏
页码：135 / 143
页数：9
相关论文
共 50 条
  • [1] Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
    Uy, Natalie
    Nadeau, Michelle
    Stahl, Maximilian
    Zeidan, Amer M.
    JOURNAL OF BLOOD MEDICINE, 2018, 9 : 67 - 74
  • [2] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali N.
    Rodriguez, Vilmarie
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    O'Brien, Maureen M.
    McNeer, Jennifer L.
    Quereshi, Amrana
    Cabannes, Aurelie
    Schlegel, Paul
    Rossig, Claudia
    Dalla-Pozza, Luciano
    August, Keith
    Alexander, Sarah
    Bourquin, Jean-Pierre
    Zwaan, Michel
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Rheingold, Susan R.
    LEUKEMIA, 2019, 33 (04) : 884 - 892
  • [3] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 884 - 892
  • [4] Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 1061 - 1062
  • [5] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
    DeAngelo, Daniel J.
    Advani, Anjali S.
    Marks, David, I
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    Jabbour, Elias
    Merchant, Akil
    Wang, Tao
    Vandendries, Erik
    Neuhof, Alexander
    Kantarjian, Hagop
    O'Brien, Susan
    BLOOD CANCER JOURNAL, 2020, 10 (08)
  • [6] Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
    Luca Bertamini
    Jacopo Nanni
    Giovanni Marconi
    Mariachiara Abbenante
    Valentina Robustelli
    Francesco Bacci
    Antonella Matti
    Stefania Paolini
    Chiara Sartor
    Silvia Lo Monaco
    Maria Chiara Fontana
    Stefano De Polo
    Michele Cavo
    Antonio Curti
    Giovanni Martinelli
    Cristina Papayannidis
    BMC Cancer, 18
  • [7] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Irina Proskorovsky
    Yun Su
    Kyle Fahrbach
    Erik Vandendries
    Véronique Pagé
    Uchenna Onyekwere
    Yunyang Wang
    Joseph C. Cappelleri
    Matthias Stelljes
    Advances in Therapy, 2019, 36 : 2147 - 2160
  • [8] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
    Daniel J. DeAngelo
    Anjali S. Advani
    David I. Marks
    Matthias Stelljes
    Michaela Liedtke
    Wendy Stock
    Nicola Gökbuget
    Elias Jabbour
    Akil Merchant
    Tao Wang
    Erik Vandendries
    Alexander Neuhof
    Hagop Kantarjian
    Susan O’Brien
    Blood Cancer Journal, 10
  • [9] Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
    Bertamini, Luca
    Nanni, Jacopo
    Marconi, Giovanni
    Abbenante, Mariachiara
    Robustelli, Valentina
    Bacci, Francesco
    Matti, Antonella
    Paolini, Stefania
    Sartor, Chiara
    Lo Monaco, Silvia
    Fontana, Maria Chiara
    De Polo, Stefano
    Cavo, Michele
    Curti, Antonio
    Martinelli, Giovanni
    Papayannidis, Cristina
    BMC CANCER, 2018, 18
  • [10] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Proskorovsky, Irina
    Su, Yun
    Fahrbach, Kyle
    Vandendries, Erik
    Page, Veronique
    Onyekwere, Uchenna
    Wang, Yunyang
    Cappelleri, Joseph C.
    Stelljes, Matthias
    ADVANCES IN THERAPY, 2019, 36 (08) : 2147 - 2160
12345